Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126061 · ClinicalTrials.gov registry record · Phase 3
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00126061: Completed Phase 3 study, sponsored by Solvay Pharmaceuticals.
NCT00126061 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00126061, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in male patients.
Interventions
- DRUG Tedisamil sesquifumarate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-10 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
What the finished NCT00126061 record still lists
NCT00126061 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Tedisamil sesquifumarate is the first listed.
NCT00126061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00126061 about?
NCT00126061 is a clinical study titled "Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects". The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in male patients.
What is the current status of trial NCT00126061?
This trial is currently completed. It is a Phase 3 study. The study started on 2004-10. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00126061?
The interventions under investigation include: Tedisamil sesquifumarate (DRUG).
Who is sponsoring clinical trial NCT00126061?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia